GPR35 and endothelial dysfunction: Another notable aspect of the current study is the discovery of Thonningianin A and Carfilzomib as potential therapeutic agents for mitigating aging‐related endothelial dysfunction impaired vasodilation by restoring the interaction between TRPV4 and GPR35.